Prevenar 20 (PCV20) Is a One-Time Lifetime Vaccination for Most Adults
For the vast majority of adults, Prevenar 20 (PCV20) is administered as a single dose that completes the pneumococcal vaccination series for life—no routine booster doses are recommended after PCV20 administration. 1, 2
Standard One-Time Dosing
Adults aged ≥65 years who receive PCV20 require only one dose to complete their pneumococcal vaccination series, with no additional pneumococcal vaccines needed thereafter. 1, 2, 3
Adults aged 19–64 years with chronic medical conditions (diabetes, chronic heart/lung/liver disease, smoking) or immunocompromising conditions who receive PCV20 complete their pneumococcal series with that single dose. 1, 4
The FDA-approved dosing for adults is a single 0.5 mL intramuscular injection, administered once. 3
Why PCV20 Completes the Series
PCV20 provides comprehensive serotype coverage (20 pneumococcal serotypes) and generates robust immune responses with T-cell dependent immunity and immunologic memory, eliminating the need for additional pneumococcal vaccines including PPSV23. 5, 1, 6
The 2023 ACIP guidelines explicitly state that when PCV20 is administered, the pneumococcal vaccination series is complete and should not be followed by another dose of PPSV23 or any other pneumococcal vaccine. 5, 1
This represents a major simplification from older regimens that required sequential PCV13 followed by PPSV23 doses. 4
Timing for Adults with Prior Pneumococcal Vaccination
Even adults who previously received other pneumococcal vaccines receive PCV20 only once:
Adults who previously received only PPSV23 should receive a single dose of PCV20 at least 1 year after the last PPSV23 dose, which then completes the series. 5, 1, 2
Adults who previously received only PCV13 should receive a single dose of PCV20 at least 1 year after the PCV13 dose, completing the series. 5, 1, 7
Adults who previously received both PCV13 and PPSV23 may receive an optional single dose of PCV20 through shared clinical decision-making if ≥5 years have elapsed since the last pneumococcal vaccine, which then completes the series. 5, 1, 7
The Only Exception: Hematopoietic Stem Cell Transplant (HSCT) Recipients
Adults who undergo HSCT require a special 4-dose series of PCV20 starting 3–6 months after transplant: three doses given 4 weeks apart, followed by a fourth dose at least 6 months after the third dose or at least 12 months after HSCT (whichever is later). 1
This is the only scenario in which multiple doses of PCV20 are recommended; all other adult populations receive a single lifetime dose. 1
Clinical Trial Evidence Supporting Single-Dose Efficacy
Phase 3 trials demonstrated that a single dose of PCV20 induced robust immune responses to all 20 serotypes in adults ≥65 years, regardless of prior pneumococcal vaccination history (including those previously vaccinated with PCV13, PPSV23, or both). 8, 6
PCV20 was well tolerated with a safety profile comparable to PCV13, supporting its use as a single-dose regimen. 3, 8, 6
Common Pitfalls to Avoid
Do not administer PPSV23 after PCV20—the series is already complete and adding PPSV23 is unnecessary and not recommended. 1, 7
Do not give repeat doses of PCV20 in routine clinical practice (except for HSCT recipients); once administered, the pneumococcal vaccination is complete for life. 1, 2
Re-evaluate pneumococcal vaccination status when adults with chronic conditions turn 65 years old, as they may need PCV20 if they only received PPSV23 earlier in life, but this is still just one additional dose, not ongoing boosters. 5, 1
Updated 2024 Recommendations
- As of October 2024, ACIP expanded PCV recommendations to include all adults aged ≥50 years (previously ≥65 years), but the single-dose approach remains unchanged—one lifetime dose of PCV20 completes the series. 9